FAK and EGFR targeted RNA interference plasmid-lipidosome antineoplastic complex

Abstract

The invention discloses the tumor gene therapy field, which particularly relates to a RNA interference plasmid-liposome resistant tumor complex of targeting FAK and EGFR. A FAK and EGFR double-gene RNA interference vector prepared by the invention can effectively inhibit the growth of the lung cancer cell of human and can induce the apoptosis; the tumor inhibiting experiment in the vivo also indicates that the FAK and EGFR double-gene RNA interference vector-liposome resistant tumor complex can obviously inhibit the growth of a plurality of the tumor, and the lifetime of the tumor bearing mice is prolonged. In the invention, the FAK and EGFR double-gene RNA interference vector is wrapped through the cationic liposome, and the chemotherapy and the radiotherapy are taken as the resistant tumor medicine of the active component together, compared with each individual operation, the resistant tumor effect is obviously optimized, and both used amounts can be reduced. By adopting the invention, the effect is obvious, the dose can be greatly reduced, the life quality of the patient is improved, and thereby the invention has a good market developing prospect.

Description

technical field [0001] The invention belongs to the field of tumor gene therapy, and in particular relates to an RNA interference carrier-liposome anti-tumor complex targeting FAK and EGFR. Background technique [0002] At present, the gene therapy of tumor has been developed vigorously and rapidly, but so far, there are still many problems to be solved. Among them, the problems that need to be solved urgently are: currently there are too few genes used for tumor gene therapy, and there are not many genes that can inhibit tumor growth, so it is urgent to provide more available genes; in addition, due to the occurrence, development, metastasis, etc. The process is a complex network system involving multiple genes and multiple signaling pathways, so a single gene therapy or a single treatment method often has limited efficacy. Therefore, the focus of future gene therapy development will be to mine and identify genes with clinical therapeutic value, to explore the combination ...

AI Technical Summary

Problems solved by technology

Among them, the problems that need to be solved urgently are: currently there are too few genes used for tumor gene therapy, and there are not many genes that can inhibit tumor growth, so it is urgent to provide more available genes; in addition, due to the occurrence, development, metastasis, etc. The process is a complex network system involving multiple genes and multiple signaling pathways, so single gene therapy or single therapy often has limited efficacy

[0005] At present, RNA interference has been widely used in tumor treatment research, but most of them use chemically synthesized siRNA to treat tumors, and chemically synthesized siRNA therapy has the following disadvantages: chemically synthesized siRNA requires a large amount of use, high cost of use, and difficulty in industrialization Large; chemically synthesized siRNA has poor stability and short time of action in the body, and requires high technical requirements for operators every time it is used; multiple infusions also have a negative impact on the quality of life of patients

At the same time, judging from literature reports, the RNA interference effect of a single gene is often not very ideal, because the occurrence, development, metastasis, and invasion of tumors are a complex process involving multiple genes and multiple steps, which may involve multiple genes, multiple Therefore, RNA interference therapy targeting multiple target genes may be a better choice, and the effect may be better. At the same time, double-gene or even multi-gene RNA interference therapy is used in combination with chemotherapy and radiotherapy in clinical tumor treatment. It may be more promising, but there is no relevant report so far

Images